The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 3047 of March 2, 2020, Tuscany Regional Healthcare has published assessments of eight medical devices of various therapeutic areas.

Patients with a newly diagnosed glioblastoma will have an opportunity to benefit from the therapy with tumor-treating fields (TTF) at the expense of statutory health insurance. The Federal Joint Committee (G-BA) decided on March 20, 2020, the details concerning the indications and the quality assurance measures that will apply when prescribing this outpatient treatment method.

In Norway, the mini-HTA for Tendyne Mitral Valve System designed for transapical implantation within the native mitral valve without the need for open-heart surgery and concomitant surgical removal of the failed native valve was released at the end of January 2020. The method was determined as efficient and safe. It was recommended to be introduced as part of the clinical routine in the hospital.

OPCS-4 is a statistical classification for clinical coding of hospital interventions and procedures undertaken by the NHS. On 4 November 2019, OPCS 4.9 Classification of Interventions and Procedures was released. The implementation date is 1 April 2020.

On March 27, 2020, the BMSGPK release the notes with the rules on diagnosis coding and administrative documentation for COVID-19 in hospitals as part of the project "Performance-based hospital financing (LKF)."

The French High Authority for Health (HAS) regularly publishes new decisions about add-on reimbursement for medical devices. The decisions made in February 2020 concern various types of devices, for example, cardiovascular and orthopaedic devices, diabetes management systems, and other types of devices. A total of 27 decisions were made.

Balneophototherapy becomes covered by the National Association of Statutory Health Insurance Funds (GKV) for patients suffering from moderate to severe neurodermatitis. The Federal Joint Committee (G-BA) decided to include this treatment option to contract medical care on March 20, 2020.

In March 2020, the Nomenclature was updated. The update brought changes regarding the creation of new codes, deletion of codes, modification of existing codes, and reimbursement conditions.

On March 5, 2020, the NHS Innovation Accelerator (NIA) announced the 11 high impact innovations that will enter the national accelerator in 2020. As outlined in the NHS Long Term Plan, the technologies that enter the award-winning NIA provide solutions that help prioritize areas for NHS.

On March 30, 2020, the French High Authority for Health, has published the opinion of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS) regarding the Impella 5.0 device. The clinical added value was graded with level II (important) for the post-cardiotomy cardiogenic shock indication. After the negotiation with CEPS, Impella might be the first short-term VAD to enter add-on reimbursement list LPPR.

The report presents a summary of the reimbursement situation for minimally invasive treatment of prostate cancer in Europe. The following procedures are considered under the scope of analysis: high intensity focused ultrasound (HIFU), cryoablation, focal laser ablation, radiofrequency ablation, microwave thermal ablation of the prostate. Open and laparoscopic radical prostatectomy, as well as external radioation therapy and low-dose-rate barchytherapy, are considered as comparators. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey.